Invivyd Total Cash From Operating Activities Over Time
| IVVD Stock | USD 0.49 0.02 4.31% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Invivyd Performance and Invivyd Correlation. Invivyd |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Invivyd. If investors know Invivyd will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Invivyd listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.95) | Revenue Per Share 0.02 | Return On Assets (0.54) | Return On Equity (0.97) |
The market value of Invivyd is measured differently than its book value, which is the value of Invivyd that is recorded on the company's balance sheet. Investors also form their own opinion of Invivyd's value that differs from its market value or its book value, called intrinsic value, which is Invivyd's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Invivyd's market value can be influenced by many factors that don't directly affect Invivyd's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Invivyd's value and its price as these two are different measures arrived at by different means. Investors typically determine if Invivyd is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Invivyd's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Cash From Operating Activities Analysis
Compare Invivyd and related stocks such as Exscientia ADR, Recursion Pharmaceuticals, and Atea Pharmaceuticals Total Cash From Operating Activities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RXRX | (57 M) | (57 M) | (57 M) | (57 M) | (57 M) | (57 M) | (57 M) | (57 M) | (57 M) | (57 M) | (45.4 M) | (158.6 M) | (83.5 M) | (287.8 M) | (273.4 M) |
| AVIR | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (12.8 M) | 296.7 M | (87 M) | (121 M) | (85.4 M) | (81.1 M) |
| UBX | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (38.4 M) | (56.6 M) | (72.4 M) | (78.3 M) | (45.1 M) | (51 M) | (37.1 M) | (38.9 M) |
| RGNX | (3 M) | (3 M) | (3 M) | (3 M) | (2.4 M) | (22.5 M) | (48.6 M) | (58 M) | 104.6 M | (107.7 M) | (54.1 M) | 218.9 M | (207.5 M) | (218.4 M) | (207.5 M) |
| ANEB | (150.8 K) | (150.8 K) | (150.8 K) | (150.8 K) | (150.8 K) | (150.8 K) | (150.8 K) | (150.8 K) | (150.8 K) | (150.8 K) | (4.9 M) | (5.4 M) | (9.7 M) | (8.1 M) | (8.5 M) |
| ABEO | 658 K | (7.6 M) | (4 M) | 1000 | (1.6 M) | (10.4 M) | (13 M) | (22.9 M) | (39.1 M) | (62.8 M) | (35 M) | (65.7 M) | (43.5 M) | (37 M) | (35.2 M) |
| BDTX | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (8.5 M) | (24.7 M) | (52.1 M) | (100.1 M) | (85.1 M) | (66.7 M) | (70.1 M) |
| GBIO | (28.1 M) | (28.1 M) | (28.1 M) | (28.1 M) | (28.1 M) | (28.1 M) | (28.1 M) | (28.1 M) | (28.1 M) | (40.3 M) | (70.1 M) | (91.8 M) | (102.4 M) | (52.7 M) | (55.4 M) |
| KRON | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (15.1 M) | (37.9 M) | (117.9 M) | (90.9 M) | (78.6 M) | (82.5 M) |
| ERAS | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (32.7 M) | (79.6 M) | (103.3 M) | (101.2 M) | (106.3 M) |
| CCCC | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | 55.6 M | (67.2 M) | (87 M) | (105.9 M) | (106.8 M) | (101.5 M) |
| EWTX | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (9.2 M) | (14.6 M) | (33.5 M) | (52.6 M) | (91.9 M) | (87.4 M) |
| PASG | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (39.9 M) | (80.5 M) | (126.9 M) | (118.2 M) | (78.3 M) | (82.2 M) |
| APVO | (51.4 M) | (51.4 M) | (51.4 M) | (51.4 M) | (47 M) | (48.8 M) | (36.9 M) | (41.6 M) | (51.4 M) | (42.4 M) | (29.3 M) | (21.7 M) | (21 M) | (11.7 M) | (12.3 M) |
Invivyd and related stocks such as Exscientia ADR, Recursion Pharmaceuticals, and Atea Pharmaceuticals Total Cash From Operating Activities description
My Equities
My Current Equities and Potential Positions
| Invivyd | IVVD |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.488
Check out Invivyd Performance and Invivyd Correlation. For information on how to trade Invivyd Stock refer to our How to Trade Invivyd Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Invivyd technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.